AU2021343475A1 - Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) - Google Patents

Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) Download PDF

Info

Publication number
AU2021343475A1
AU2021343475A1 AU2021343475A AU2021343475A AU2021343475A1 AU 2021343475 A1 AU2021343475 A1 AU 2021343475A1 AU 2021343475 A AU2021343475 A AU 2021343475A AU 2021343475 A AU2021343475 A AU 2021343475A AU 2021343475 A1 AU2021343475 A1 AU 2021343475A1
Authority
AU
Australia
Prior art keywords
cltx
cca
blood
dosing regimen
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021343475A
Other languages
English (en)
Other versions
AU2021343475A9 (en
Inventor
Simon BRUCE
Michael T. Collins
Jonathan Fox
Rachel I. GAFNI
Iris R. HARTLEY
Ali KOMEYLI
Karen A. POZO
Mary Scott ROBERTS
Kelly B. L. ROSZKO
Ramei SANI-GROSSO
Ananth SRIDHAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Calcilytix Therapeutics Inc
Original Assignee
Government of the United States of America
Calcilytix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America, Calcilytix Therapeutics Inc filed Critical Government of the United States of America
Publication of AU2021343475A1 publication Critical patent/AU2021343475A1/en
Publication of AU2021343475A9 publication Critical patent/AU2021343475A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2021343475A 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1) Pending AU2021343475A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063080165P 2020-09-18 2020-09-18
US63/080,165 2020-09-18
US202163159397P 2021-03-10 2021-03-10
US63/159,397 2021-03-10
PCT/US2021/050677 WO2022060987A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Publications (2)

Publication Number Publication Date
AU2021343475A1 true AU2021343475A1 (en) 2023-06-01
AU2021343475A9 AU2021343475A9 (en) 2024-05-02

Family

ID=78087574

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021343475A Pending AU2021343475A1 (en) 2020-09-18 2021-09-16 Triphenyl calcilytic compounds for the treatment of autosomal dominant hypocalcemia type 1 (adh1)

Country Status (10)

Country Link
US (1) US20220087961A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213829A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542932A (cg-RX-API-DMAC7.html)
KR (1) KR20230112609A (cg-RX-API-DMAC7.html)
AU (1) AU2021343475A1 (cg-RX-API-DMAC7.html)
CA (1) CA3192684A1 (cg-RX-API-DMAC7.html)
IL (1) IL301409A (cg-RX-API-DMAC7.html)
MX (1) MX2023003129A (cg-RX-API-DMAC7.html)
TW (1) TW202227046A (cg-RX-API-DMAC7.html)
WO (1) WO2022060987A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116648243A (zh) 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂
WO2024220796A1 (en) * 2023-04-21 2024-10-24 Calcilytix Therapeutics, Inc. Treatment of hypoparathyroidism using triphenyl calcilytic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050460A1 (es) * 2003-04-23 2005-07-08 Japan Tobacco Inc COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO)
CN116648243A (zh) * 2020-08-04 2023-08-25 柯西立提克斯疗法有限公司 三苯基钙敏感化合物的制剂

Also Published As

Publication number Publication date
EP4213829A1 (en) 2023-07-26
WO2022060987A1 (en) 2022-03-24
IL301409A (en) 2023-05-01
MX2023003129A (es) 2023-08-04
US20220087961A1 (en) 2022-03-24
TW202227046A (zh) 2022-07-16
KR20230112609A (ko) 2023-07-27
AU2021343475A9 (en) 2024-05-02
CA3192684A1 (en) 2022-03-24
JP2023542932A (ja) 2023-10-12

Similar Documents

Publication Publication Date Title
Christensson et al. Hypercalcemia and primary hyperparathyroidism: prevalence in patients receiving thiazides as detected in a health screen
US20220323445A1 (en) Reducing immunogenicity to pegloticase
KR100445946B1 (ko) 폐고혈압 치료법
Palmer A physiologic-based approach to the evaluation of a patient with hyperkalemia
US6645959B1 (en) Method for treating postoperative ileus
US20220087961A1 (en) Treatment methods of triphenyl calcilytic compounds
US20220409620A1 (en) Reducing immunogenicity to pegloticase
Bacchetta et al. X-linked hypophosphatemia and burosumab: practical clinical points from the French experience
Clayton et al. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants
US20090239844A1 (en) Ace inhibitor-vasopressin antagonist combinations
Sigalet et al. A safety and pharmacokinetic dosing study of glucagon-like peptide 2 in infants with intestinal failure
CN116916907A (zh) 用于治疗常染色体显性遗传性低钙血症1型(adh1)的三苯基溶钙化合物
EP1253945B1 (en) Ace inhibitor-vasopressin antagonist combinations
EP1280555B1 (en) Pharmaceutical composition comprising furosemide and conivaptan for the treatment of congestive heart failure
TW202506101A (zh) 使用三苯基鈣敏感性化合物之副甲狀腺機能低下症治療
US20240423961A1 (en) 1h-1,2,3-triazole-4-carboxylic acids for treatment of hyperoxaluria and kidney stones
US20250222003A1 (en) Pharmaceutical composition for treating solid tumors
WO2026032924A1 (en) Camlipixant in combination with cyp3a4 and/or cyp2c8 inducers for use in the treatment of chronic cough
Sato et al. Hypomagnesemia Causing Convulsions in a Patient Taking a Proton Pump Inhibitor: A Case Report
Moretz Drug Class Literature Scan: Iron Replacement, Oral
Matsumoto et al. Hypercalcemia with the Oral Administration of Active Vitamin D3 and Chinese Herbal Medicine
WO2025235883A1 (en) Acoramidis for use in the treatment of renal dysfunction
CN120981229A (zh) 用于治疗先天性肾上腺皮质增生症的组合物和方法
CN118829427A (zh) 治疗腹型肥胖、高甘油三酯血症和/或血糖受损受试者的方法
Tucker Novel Insulin Cuts Hypoglycemia, Weight Gain

Legal Events

Date Code Title Description
SREP Specification republished